Condition: Metastatic Uveal Melanoma · Uveal Melanoma, Metastatic · Uveal Melanoma, Recurrent · Sponsor: Novelwise Pharmaceutical Corporation
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. The study will help doctors learn about the side effects of NBM-BMX, how the drug is processed in the body, and whether it may slow down or shrink tumors. Participants will take NBM-BMX as a capsule by mouth twice daily on an empty stomach with at least six ounces (180 mL) of water. No food or drink (other than water) should be consumed for at least two hours after each dose. Participants will visit the clinic about once every week or two for exams and blood tests while taking NBM-BMX. After stopping treatment, a follow-up visit will occur about 30 days later. Treatment may continue as long as the cancer does not get worse and side effects remain manageable.
This description comes directly from the study's public registry record.
Annie Pai, PhD · 1 (910) 297-9045 · NWP-US-info.tw@novelwisepharma.com
John Soong, MD · johnjsoong@novelwisepharma.com
Always discuss trial participation with your own doctor first.
| Honor Health Resarch Institute | Scottsdale, Arizona, United States | Recruiting |
| Sarah Cannon Research Institute (SCRI) - Denver HealthONE Location | Denver, Colorado, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07136181